RJA
ATNM icon

Raymond James & Associates’s Actinium Pharmaceuticals ATNM Stock Holding History

Raymond James & Associates’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-511
Closed -$3K – 3525
2020
Q1 		$3K Hold
511
– – ﹤0.01% 3476
2019
Q4 		$3K Hold
511
– – ﹤0.01% 3649
2019
Q3 		$4K Hold
511
– – ﹤0.01% 3583
2019
Q2 		$4K Hold
511
– – ﹤0.01% 3611
2019
Q1 		$7K Sell
511
-33
-6% -$527 ﹤0.01% 3580
2018
Q4 		$6K Buy
+544
New +$9.28K ﹤0.01% 3484
2017
Q2 		– Sell
-511
Closed -$23K – 3342
2017
Q1 		$23K Buy
+511
New +$19.6K ﹤0.01% 3202

Other funds holding ATNM

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Raymond James & Associates's ATNM Position: Q2 2020 in Review

Raymond James & Associates sold out of Actinium Pharmaceuticals (ATNM) in Q2 2020, closing a stake of 511 shares — an estimated $3K sold.

Raymond James & Associates first reported a position in ATNM in Q1 2017 and held it in 7 quarters. The position peaked at $23K in Q1 2017. 59 funds tracked by Wall St. Rank hold ATNM as of Q2 2020.

  • Raymond James & Associates reported no remaining Actinium Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Raymond James & Associates sold 511 Actinium Pharmaceuticals shares in Q2 2020, an estimated $3K.
  • Raymond James & Associates first reported a position in Actinium Pharmaceuticals in Q1 2017 and held it in 7 quarters.
  • Raymond James & Associates's Actinium Pharmaceuticals position peaked at $23K in Q1 2017.
  • 59 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2020.

Based on Raymond James & Associates's 13F filing for Q2 2020, filed 28 Jul 2020.